Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study

135Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

Abstract

This study evaluated the effects of initial versus delayed treatment with a drug combination on blood pressure (BP) control and the risk of cardiovascular (CV) events in hypertensive patients. Clinical trials suggest that the time to BP control is an important determinant of long-term outcomes, but real-world evidence is scarce. Using electronic medical charts (2005-2009), we retrospectively analyzed 1762 adult patients with BP elevation initiating combination therapy matched 1:1 with similar patients initiating monotherapy and later switched to combination therapy. Incidence rate ratios of CV events (myocardial infarction, stroke/transient ischemic attack, or hospitalization for heart failure) or all-cause death and Kaplan-Meier analyses of time to BP control were compared between cohorts. Hazard ratios indicating the effects of initial treatment on CV events and BP control were estimated using time-varying Cox proportional hazard models. Initial combination therapy was associated with a significant reduction in the risk of CV events or death (incidence rate ratio, 0.66 [95% confidence interval, 0.52-0.84]; P=0.0008). After 6 months of therapy, 40.3% and 32.6% of patients with initial versus delayed combination treatment reached BP control, respectively. Achieving target BP was associated with a statistically significant risk reduction of 23% for CV events or death (hazard ratio, 0.77 [95% confidence interval, 0.61-0.96]; P=0.0223); the residual effect of initial combination therapy did not reach statistical significance (hazard ratio, 0.84 [95% confidence interval, 0.68-1.03]; P=0.0935). Initial combination therapy was associated with a significant risk reduction of cardiovascular events. More rapid achievement of target BP was found to be the main contributor to the estimated risk reduction. © 2012 American Heart Association, Inc.

References Powered by Scopus

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

11236Citations
N/AReaders
Get full text

Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies

8457Citations
N/AReaders
Get full text

Heart disease and stroke statistics-2011 update: A report from the American Heart Association

4519Citations
N/AReaders
Get full text

Cited by Powered by Scopus

2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)

1360Citations
N/AReaders
Get full text

Brazilian guidelines of hypertension - 2020

443Citations
N/AReaders
Get full text

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

256Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gradman, A. H., Parisé, H., Lefebvre, P., Falvey, H., Lafeuille, M. H., & Duh, M. S. (2013). Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study. Hypertension, 61(2), 309–318. https://doi.org/10.1161/HYPERTENSIONAHA.112.201566

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 23

48%

Researcher 11

23%

Professor / Associate Prof. 10

21%

Lecturer / Post doc 4

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 35

70%

Pharmacology, Toxicology and Pharmaceut... 9

18%

Agricultural and Biological Sciences 3

6%

Biochemistry, Genetics and Molecular Bi... 3

6%

Save time finding and organizing research with Mendeley

Sign up for free